Fig. 2From: Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trialSchedule of events. CRP C-reactive protein, DSA donor-specific antibody, eGFR estimated glomerular filtration rate, HDL high density lipoprotein, Ig immunoglobulin, LDL low density lipoprotein, PD pharmacodynamics, PK pharmacokinetics, TTV Torque Teno virusBack to article page